Abstract:Background: Lung cancer is the most lethal cancer in men and women. Recently, it has been reported that circu-lating tumor cells (CTCs) are sensitive and reliable biomarkers for tracing relapse and metastasis of cancer patients. Many studies also showed that immune cellular dysfunctions in lung cancer patients are major reasons for cancer development. In this study, we explored the clinical significance of CTCs and T lymphocyte subtypes in lung cancer patients. Methods: A total of 92 patients with diagnosed lung cancer, including 23 squamous-cell carcinoma and 69 adenocarcinoma, were enrolled in this study. Another 10 patients with non-carcinoma nodules in their lungs were also recruited as a control group. Peripheral blood samples were drawn from the patients with lung cancer and from the control cases before the treatment. The identification of CTCs was carried out by a PatrolCTC detection method. The T lymphocyte subtypes were characterized by flow cytometry (FACS). Cytokines interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-17A (IL-17A), interleukin-10 (IL-10), and interferon  (IFN-) were detected by meso scale discovery (MSD) assay. Results: Out of the enrolled patients, 69 (75%) patients with non-small cell lung cancer (NSCLC) were male and 23 (25 %) were female. Smoking and non-smoking history was 50% (46 cases) each. The case numbers for I - IV tumor-node-metastasis (TNM) stages were 23 (25.0%), 28 (30.4%), 16 (17.4%), and 25 (27.2%), respectively. The positive rates of the CTCs before treatment were 8.7% (2/23), 17.6% (5/28), 81.3% (13/16), and 100% (25/25) in stage I, II, III, and IV patients, respectively. Total CTCs, mixed CTCs, and mesenchymal CTCs (MCTCs) were strongly related to the progression-free survival (PFS) of the patients. In addition, total CTCs (≥ 6) and positive MCTCs also significantly correlated with recurrence and metastasis. The patients with high CTCs also had low levels of CD4, CD4/CD8 ratio, IL-2, and IFN. In contrast, IL-10 in high CTCs patients was significant elevated. These results indicate that the CTC numbers in lung cancer patients are an independent indicator for a worse PFS. Conclusions: Higher total CTCs, mixed CTCs, and MCTCs in peripheral blood were significant biomarkers for predicting the prognosis of lung cancer patients. High CTCs also had a strong correlation with weak cellular immunity functions.

THE LEVEL AND SIGNIFICANCE OF T LYMPHOCYTE SUB-GROUP IN PERIPHERAL BLOOD IN PATIENTS WITH CANCER

Clinical Significance of Peripheral Blood and Tumor Tissue Lymphocyte Subsets in Cervical Cancer Patients

[Quantitative Studies on Expression of Peripheral Blood CD44 and CD54 in Non-Small Cell Lung Carcinoma].

The Unique Characteristic in Peripheral Immune Cells in Patients with Advanced Hepatocellular Carcinoma.

Analysis of NK/T and Treg cell in peripheral blood of patients with different malignancies during the chemotherapy

[Tumor Lymphangiogenesis in Cervical Squamous Cell Carcinoma and Its Clinical Significance].

The Clinical Significance of the CD44v6 Expression in Peripheral Blood Mononuclear Cell and Cancerous Tissue of Patients with Gastric Cancer

Detection of T Cell Subsets in Peripheral Blood of Cervical Cancer and Its Clinical Significance

Clinical Significance of Immunologically Competent Cells in Peripheral Blood from Patients with Malignant Carcinomas

Analysis on the Change of Peripheral Blood T Lymphocyte Subsets Before and after Chemotherapy in Patients with Non-Small Cell Lung Cancer

Change and significance of peripheral blood lymphocyte immunophenotype in cutaneous T-cell lymphoma

The Predictive Value of Changes in the Absolute Counts of Peripheral Lymphocyte Subsets for Progression and Prognosis in Breast Cancer Patients

The Clinical Values of Circulating Tumor Cells and T Lymphocyte Subsets in Predicting a Prognosis of Lung Cancer

Expression analysis of lymphocyte subsets and lymphocyte-to-monocyte ratio: reveling immunosuppression and chronic inflammation in breast cancer

Effect of Peripheral Blood Lymphocytes on Prognosis of Multiple Cancers

Clinical significance of expression rate of cytokines in peripheral blood cells of patients with lung cancer

Relation between peripheral blood active circulating tumor cell and clinical characteristics of non-small cell lung cancer

Study on Peripheral Blood T Lymphocyte Subsets of Patients with Lung Cancer and Lung Infection

Study on the subset of T lymphocyte and CD4 + CD25 + regulatory cells in peripheral blood in patients with gastric cancer

Circulating activated immune cells as a potential blood biomarkers of non-small cell lung cancer occurrence and progression

Peripheral Lymphocyte Populations in Ovarian Cancer Patients and Correlations with Clinicopathological Features